CD4 and COVID-19: These findings suggest that the early-expressed conserved antigens belonging to the RTC region, which are selectively recognized by CD4+ and CD8+ T cells from asymptomatic COVID-19 patients and “SARS-CoV-2 aborters,” are ideal targets for inclusion in a next-generation CoV vaccine33, 34, 35, 36.